Technical Analysis for SGMO - Sangamo BioSciences, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Fell Below 20 DMA | Bearish | 3.09% | |
50 DMA Support | Bullish | 3.09% | |
50 DMA Support | Bullish | 1.59% | |
50 DMA Support | Bullish | 0.72% | |
Outside Day | Range Expansion | 0.72% | |
50 DMA Support | Bullish | 1.59% | |
Narrow Range Bar | Range Contraction | 1.59% | |
50 DMA Support | Bullish | 1.89% | |
NR7 | Range Contraction | 1.89% | |
Narrow Range Bar | Range Contraction | 1.89% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
Rose Above 20 DMA | about 3 hours ago |
20 DMA Support | about 3 hours ago |
Rose Above 10 DMA | about 3 hours ago |
Up 3% | about 3 hours ago |
Up 2% | about 3 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 02/22/2023
Sangamo BioSciences, Inc. Description
Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States. Its ZFPs could be engineered to make ZFP nucleases (ZFNs) proteins, which could be used to modify DNA sequences in various ways; and ZFP transcription factors (ZFP TFs) proteins that could be used to turn genes on or off. The company's principal ZFP therapeutic is SB-728-T, a ZFN-modified autologous T-cell product, which is in Phase II and Phase I/II clinical trials for the treatment of human immunodeficiency virus and acquired immunodeficiency syndrome. It also develops SB-313xTZ that is in Phase I clinical trial for the treatment of glioblastoma. In addition, the company has ZFP therapeutic pre-clinical stage programs for hemophilia A and B, and huntington's disease; and proprietary programs in the areas of hemoglobinopathies and lysosomal storage disorders. Further, it has ZFP therapeutic research stage programs in the areas of other monogenic diseases, including certain immunodeficiency disorders. The company has collaboration, research, and license agreements with Shire AG; Sigma-Aldrich Corporation; Dow AgroSciences LLC; Genentech, Inc.; Open Monoclonal Technology, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. Sangamo Biosciences, Inc. was founded in 1995 and is headquartered in Richmond, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Emerging Technologies Molecular Biology Blastoma Glioblastoma Hemoglobin Immunodeficiency Transcription Hemophilia Huntington's Disease Transcription Factors Cell Product Hemophilia A Monogenic Transcription Factor Hemoglobinopathies Lysosomal Storage Disorder Lysosomal Storage Disorders Monogenic Diseases Deficiency Syndrome Dow Agrosciences Hoffmann La Roche
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 6.415 |
52 Week Low | 2.721 |
Average Volume | 1,283,966 |
200-Day Moving Average | 4.30 |
50-Day Moving Average | 3.40 |
20-Day Moving Average | 3.41 |
10-Day Moving Average | 3.46 |
Average True Range | 0.17 |
RSI | 49.24 |
ADX | 16.25 |
+DI | 21.78 |
-DI | 18.21 |
Chandelier Exit (Long, 3 ATRs) | 3.25 |
Chandelier Exit (Short, 3 ATRs) | 3.23 |
Upper Bollinger Bands | 3.69 |
Lower Bollinger Band | 3.12 |
Percent B (%b) | 0.49 |
BandWidth | 16.67 |
MACD Line | 0.03 |
MACD Signal Line | 0.01 |
MACD Histogram | 0.0149 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 3.67 | ||||
Resistance 3 (R3) | 3.70 | 3.63 | 3.63 | ||
Resistance 2 (R2) | 3.63 | 3.56 | 3.62 | 3.61 | |
Resistance 1 (R1) | 3.52 | 3.52 | 3.49 | 3.49 | 3.59 |
Pivot Point | 3.45 | 3.45 | 3.44 | 3.44 | 3.45 |
Support 1 (S1) | 3.34 | 3.38 | 3.31 | 3.31 | 3.21 |
Support 2 (S2) | 3.27 | 3.34 | 3.26 | 3.19 | |
Support 3 (S3) | 3.16 | 3.27 | 3.18 | ||
Support 4 (S4) | 3.13 |